Elite in Prostate Cancer

Igor Latorzeff

1, Rue De La Petite Vitesse, 
Toulouse, FR 
Elite in Prostate Cancer
1, Rue De La Petite Vitesse, 
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Igor Latorzeff practices in Toulouse, France. Mr. Latorzeff is rated as an Elite expert by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Lung Metastases, Cerebral Arteriovenous Malformation, Prostatectomy, and Orchiectomy.

His clinical research consists of co-authoring 134 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 80 articles and participated in 6 clinical trials in the study of Prostate Cancer.

Gender
Male

Locations

1, Rue De La Petite Vitesse, Toulouse, 31300, France
Other Locations
168 A, Rue De Grenelle, Paris, 75007, France
Brest, France
Rene, 44805, France
Avenue Du Général Harris, Caen, 14076, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Apalutamide, Luteinising Hormone Releasing Hormone agonist
Study Phase: Phase 3
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Other, Radiation, Drug
Study Drugs: Abiraterone acetate, Docetaxel
Study Phase: Phase 3
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG
Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug, Radiation
Study Drugs: Degarelix, GnRH agonist
Study Phase: Phase 3
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Metformin
Study Phase: Phase 2
Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), Vulnerable or Frail , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)
Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), Vulnerable or Frail , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Drug
Study Phase: Phase 2
Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)
Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)
Enrollment Status: Suspended
Publish Date: May 16, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

134 Total Publications

Guidelines for external radiotherapy and brachytherapy procedures: 4th edition.
Guidelines for external radiotherapy and brachytherapy procedures: 4th edition.
Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Latorzeff's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile